Full Text
Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States

Abstract

Authors

D Rao E Heidari KM Kamal AA Dashputre

Back to Volume 21, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×